These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29383038)

  • 1. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
    Kallergi G; Vetsika EK; Aggouraki D; Lagoudaki E; Koutsopoulos A; Koinis F; Katsarlinos P; Trypaki M; Messaritakis I; Stournaras C; Georgoulias V; Kotsakis A
    Ther Adv Med Oncol; 2018; 10():1758834017750121. PubMed ID: 29383038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).
    Pantazaka E; Ntzifa A; Roumeliotou A; Lianidou E; Georgoulias V; Kotsakis A; Kallergi G
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.
    Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H
    Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.
    Katsarou SD; Messaritakis I; Voumvouraki A; Kakavogiannis S; Κotsakis A; Alkahtani S; Stournaras C; Martin SS; Georgoulias V; Kallergi G
    J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.
    Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H
    Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs.
    Su X; Zhou C; Chen S; Ma Q; Xiao H; Chen Q; Zou H
    Oncol Lett; 2024 Mar; 27(3):131. PubMed ID: 38362233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
    Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
    Papadaki MA; Sotiriou AI; Vasilopoulou C; Filika M; Aggouraki D; Tsoulfas PG; Apostolopoulou CA; Rounis K; Mavroudis D; Agelaki S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
    Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8
    Kotsakis A; Kallergi G; Aggouraki D; Lyristi Z; Koinis F; Lagoudaki E; Koutsopoulos A; Georgoulias V; Vetsika EK
    Ther Adv Med Oncol; 2019; 11():1758835919853193. PubMed ID: 31217824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
    Winograd P; Hou S; Court CM; Lee YT; Chen PJ; Zhu Y; Sadeghi S; Finn RS; Teng PC; Wang JJ; Zhang Z; Liu H; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Hepatol Commun; 2020 Oct; 4(10):1527-1540. PubMed ID: 33024921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
    Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
    PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
    Cheng Y; Wang T; Lv X; Li R; Yuan L; Shen J; Li Y; Yan T; Liu B; Wang L
    Cancer Manag Res; 2020; 12():2069-2078. PubMed ID: 32256114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
    Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
    Cells; 2024 May; 13(9):. PubMed ID: 38727318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.